DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...
DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent...
Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his...
